Previous Article | Next Article 
Applied and Environmental Microbiology, January 2000, p. 310-319, Vol. 66, No. 1
0099-2240/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
An Explosive Antisense RNA Strategy for Inhibition
of a Lactococcal Bacteriophage
Shirley A.
Walker and
Todd R.
Klaenhammer*
Department of Food Science, North Carolina
State University, Raleigh, North Carolina 27695-7624
Received 23 June 1999/Accepted 19 October 1999
 |
ABSTRACT |
The coding regions of six putative open reading frames (ORFs)
identified near the phage
31 late promoter and the right cohesive end (cos) of lactococcal bacteriophage
31 were used to
develop antisense constructs to inhibit the proliferation of phage
31. Two middle-expressed ORFs (ORF 1 and ORF 2) and four
late-expressed ORFs (ORF 3 through ORF 6) were cloned individually
between the strong Lactobacillus P6 promoter and the T7
terminator (TT7) to yield a series of antisense RNA
transcripts. When expressed on a high-copy-number vector from a strong
promoter, the constructs had no effect on the efficiency of plaquing
(EOP) or the plaque size of phage
31. To increase the ratio of
antisense RNA to the targeted sense mRNA appearing during a phage
infection, the antisense cassettes containing the late-expressed ORFs
(ORF 3 through ORF 6) were subcloned to pTRK360, a low-copy-number
vector containing the phage
31 origin of replication,
ori31. ori31 allows for explosive amplification
of the low-copy-number vector upon phage infection, thereby increasing
levels of antisense RNA transcripts later in the lytic cycle. In
addition, the presence of ori31 also lowers the burst size
of phage
31 fourfold, resulting in fewer sense, target mRNAs being
expressed from the phage genome. The combination of ori31
and P6::anti-ORF 4H::TT7 resulted in a
threefold decrease in the EOP of phage
31 (EOP = 0.11 ± 0.03 [mean ± standard deviation]) compared to the presence of
ori31 alone (EOP = 0.36). One-step growth curves
showed that expression of anti-ORF 4H RNA decreased the percentage of
successful centers of infection (75 to 80% for ori31
compared to 35 to 45% for ori31 plus anti-ORF 4H), with no
further reduction in burst size. Growth curves performed in the
presence of varying levels of phage
31 showed that ori31 plus anti-ORF 4H offered significant protection to Lactococcus lactis, even at multiplicities of infection of 0.01 and 0.1. These results illustrate a successful application of an antisense
strategy to inhibit phage replication in the wake of recent
unsuccessful reports.
 |
INTRODUCTION |
Lactococcus lactis is an
industrially important member of the lactic acid bacteria used in the
fermentation of many dairy products, including sour cream,
buttermilk, and various cheeses, such as cheddar. Because of the
nature of the cheese fermentation process, bacteriophage problems
continue to appear in the dairy industry, resulting in slowed or failed
fermentation tanks and substantial economic losses. Efforts to protect
L. lactis from phage attack have led to the identification
of several phage resistance mechanisms naturally harbored by this
important microorganism. These mechanisms can be divided into four
groups: blockage of phage adsorption, blockage of phage DNA injection,
restriction/modification, and abortive mechanisms (for extensive
reviews, see references 2, 9, 10, 18, 23, and
33). These phage defense mechanisms are often
located on plasmids, many of which have been successfully transferred,
separately or in combination, to other industrial strains (6, 7,
16, 20, 29, 42, 47) to provide barriers to phage proliferation.
Despite advances in this arena, however, the appearance of new phages
capable of overcoming these defenses continues to pose a challenge to
starter culture manufacturers. In addition, the use of biotechnology to
develop highly specialized strains for specific functions may
exacerbate this problem, since repeated use can allow the accumulation
of phages capable of attacking the strain, thereby limiting its
long-term usefulness in industry (9, 23, 33).
Recent advances in the molecular biology of L. lactis and
its bacteriophages have opened the door to the development of novel, recombinant phage defense mechanisms to complement the mechanisms described above. Two interesting examples of novel phage defense mechanisms involve the alteration or replacement of chromosomal elements to inhibit phage proliferation. In one case, site-specific integration was used to inactivate sequences in the NCK203 chromosome, which contributed to the emergence of new phages insensitive to certain
resistance mechanisms (14, 36). Inactivation prevented the
evolution and subsequent proliferation of recombinant lytic phages. In
the second case, a bacteriophage receptor (pip), encoded by
the L. lactis chromosome and involved in sensitivity to
phages of the c2 species, was replaced with a mutated version
(17). The replacement, which left no nonlactococcal DNA or
antibiotic markers, resulted in a strain resistant to infection by c2
phages. In addition, phage sequences have been successfully utilized in the development of phage defense mechanisms. For example, a suicide system consisting of a phage-specific promoter from the lytic bacteriophage
31 (
31P) (41, 52) linked to a lethal
gene (the LlaI restriction cassette) (40) was
described recently (13). In this system, the infection
transcriptionally activates a phage-specific, inducible promoter to
express a lethal gene, thereby killing the host and destroying the
phage genome. Another example is phage-encoded resistance, which
provides a phage origin of replication in trans to compete
with and inhibit phage replication (22, 37). This phage
resistance mechanism was demonstrated with two origins of replication
isolated from the P335 phages,
50 (per50) (22)
and
31 (per31) (37). When present on a
low-copy-number vector, per50 and per31 result in
explosive plasmid amplification, with a concomitant reduction in phage
efficiency of plaquing (EOP) (0.42 and 0.3, respectively) and plaque
size (22, 37). On a high-copy-number vector, both cause a
significant decrease in EOP (22, 37).
In addition to the novel phage defense systems described above,
antisense technology offers another approach to exploit phage sequences
in providing barriers to phage attack. Binding of antisense RNA to the
target mRNA prevents translation, either by preventing ribosome loading
or by destabilizing the mRNA and making it more susceptible to RNase
attack (27). Naturally occurring antisense mechanisms have
been described for several systems (for reviews, see references
27 and 46). Although results have
been inconsistent, antisense strategies have also been used
successfully to control gene expression in animals (28),
plants (15), and bacteria (8). In fact, Hirashima
et al. (24, 25) utilized antisense RNA directed against
various regions of the maturation protein, coat protein, and replicase
gene to develop a novel immune system against RNA coliphage SP
proliferation. These authors found that a 30-nucleotide antisense RNA
directed against the Shine-Dalgarno sequence and base pairs just
upstream of the maturation protein was sufficient to almost completely
inhibit this phage (25).
Previous attempts to use antisense mechanisms to protect L. lactis from bacteriophage attack, however, have yielded variable results. Using the major coat protein gene, mcp, of
F4-1,
Chung et al. (5) achieved a reduction in EOP of 0.5 to 0.77, depending on the extent of the mcp gene included in the
antisense construct. In contrast, Moineau et al. (35) found
that the major structural proteins of the P335 phage ul36 were produced
in excess, making them poor targets for antisense technology. Kim et
al. (30-32) cloned an entire open reading frame (ORF)
(gp51C) of unknown function from
7-9 in an antisense
orientation. When the entire coding region was used, this antisense
construct resulted in a reduction in the EOP of
7-9 to
10
2. This same EOP reduction was observed upon infection
with phages related to
7-9, which also contained this ORF. In
addition, resistance to phage
7-9 was achieved by antisense RNA
directed to two ORFs immediately downstream of gp51C
(gp18C and gp24C), although the resistance was
far less efficient (EOP, ~0.45) than that achieved with
gp51C (32). More recently, Polzin et al. (K. M. Polzin, L. J. Collins, M. W. Lubbers, and A. W. Jarvis, Abstr. 5th Symp. Lactic Acid Bacteria, abstr. F2, 1996) used an
antisense strategy to target several ORFs from the early and late
regions of the prolate phage c2. The ORFs included e5, a
putative subunit of DNA polymerase; e12, a putative
transcription factor; l7, a major tail protein; and
l12, a terminase. No inhibition was observed at low or high
copy numbers for any of the constructs, even though there was some
evidence that the antisense constructs lowered the expression levels of
some of the ORFs. Lastly, in our laboratory, an antisense strategy was
used to target the gene encoding the transcriptional activator,
tac31A, of the phage
31 late promoter (52).
Although the anti-tac31A construct was able to significantly reduce expression from the phage promoter, it was not able to inhibit
proliferation of
31.
The variable and largely negative results with antisense technology are
unfortunate, especially since the recent availability of several
complete and partial bacteriophage genome sequences (3, 34, 45,
50) makes the design of antisense strategies a viable option. In
the present study, we have used available sequence information from
near the late promoter and the right cohesive end of phage
31
(51) to develop antisense constructs in both a
high-copy-number vector and a low-copy-number explosive vector
containing ori31, the putative phage
31 origin of
replication. The constructs allowed us to compare the efficacy of
providing high levels of antisense RNA constitutively or explosively
during the appropriate time in the phage lytic cycle.
 |
MATERIALS AND METHODS |
Strains, plasmids, and media.
The strains and plasmids used
in this study are listed in Table 1.
L. lactis subsp. lactis NCK203, the sensitive
host for bacteriophage
31, was propagated in M17 (Difco)
supplemented with 0.5% glucose (GM17) at 30°C. When appropriate,
erythromycin was added at a concentration of 2.5 µg/ml.
Escherichia coli strains were grown in Luria-Bertani broth
at 37°C with shaking, or on Luria-Bertani medium supplemented with
1.5% agar. When required, chloramphenicol was added at a concentration
of 20 µg/ml. In E. coli, erythromycin resistance was
selected on brain heart infusion agar (Difco) supplemented with 120 µg of erythromycin per ml (38).
Bacteriophage propagation and assays.
Phage
31 is a
small, isometric, cohesive-ended, lytic lactococcal bacteriophage of
the P335 species (1) with a double-stranded DNA genome of
31.9 kb. Phage
31 was propagated on NCK203 in GM17 supplemented with
10 mM CaCl2 at 30°C. EOP assays were performed as
described previously (49). Center-of-infection assays,
one-step growth curves, and burst size determinations were all
performed at 30°C as described previously (13, 48).
Plasmid and phage DNA isolation and molecular cloning.
Small-scale E. coli plasmid preparations were performed by
the alkaline-sodium dodecyl sulfate method (44). Large-scale E. coli plasmid preparations were performed with a plasmid
kit (Qiagen, Inc., Chatsworth, Calif.) according to the manufacturer's directions. Small-scale isolation of plasmids from L. lactis
was as described by O'Sullivan and Klaenhammer (39), except
that ethidium bromide was not used prior to phenol-chloroform
extraction. Phage DNA was isolated by a large-scale protocol, as
described elsewhere (43). Standard procedures were used for
the DNA manipulations described in this study (44).
Restriction enzymes and T4 DNA ligase were obtained from Boehringer
Mannheim Biochemicals (Indianapolis, Ind.) and used according to the
manufacturer's instructions. All DNA used in cloning reactions was
first gel purified with the QIAEX II DNA extraction kit (Qiagen, Inc.).
Bacterial transformations.
Ligations were transformed into
RbCl-competent E. coli XL1-Blue. RbCl-competent E. coli cells were prepared by the procedure of Hanahan
(19), modified as described by Dinsmore and Klaenhammer (11). Cells were frozen at
70°C in 100-µl aliquots and
transformed by the procedure described previously for
CaCl2-competent cells (44). After screening for
the proper insert in E. coli, plasmids were electroporated
into L. lactis by a modified procedure of Holo and Nes
(26), as described previously (52).
PCR and DNA sequencing.
PCR was performed with
Taq DNA polymerase (Boehringer Mannheim Biochemicals)
according to the manufacturer's instructions. In each case, 40 cycles
were used to amplify the region of interest. Annealing temperatures
were 5 to 10°C below the lowest Tm of each primer pair. To facilitate cloning of PCR products, appropriate restriction enzyme sites were designed into the 5' ends of the primers.
Primer sequences used to amplify the different ORFs described in this
manuscript are shown in Table 2.
RNA manipulations.
RNA was isolated from L. lactis subsp. lactis NCK203 at various times during the
phage infection cycle by using TRIzol reagent (Gibco-BRL, Gaithersburg,
Md.) as described by Dinsmore and Klaenhammer (11). Slot
blot Northern hybridizations were performed on a Bio-Rad (Richmond,
Calif.) apparatus according to the manufacturer's protocol. An
equivalent amount of RNA from each time point (approximately 10 µg)
was denatured and applied to a Zeta probe membrane (Bio-Rad). The RNA
was UV cross-linked to the membrane with the auto-cross-link cycle of
the Stratagene Stratalinker (Stratagene, La Jolla, Calif.) and then
hybridized to a 32P-labeled probe at 65°C to measure ORF
4 and ORF 5 mRNA levels, or at 55°C to measure anti-ORF 4H RNA
levels. The ORF 4 and ORF 5 probes used to measure levels of target,
sense mRNA after phage
31 infection were 32P-labeled by
the multiprime DNA labeling system (Amersham, Piscataway, N.J.). The
72-bp oligonucleotide used to measure levels of antisense ORF 4H RNA
was 32P-labeled with T4 polynucleotide kinase (Boehringer
Mannheim) and [
-32P]ATP (NEN, Boston, Mass.) per the
manufacturer's instructions.
 |
RESULTS |
Construction of antisense cassettes in high-copy-number and
explosive vectors.
Available sequence information from near the
right cohesive end of the lytic, lactococcal bacteriophage
31 (Fig.
1) (51) was used to design
antisense cassettes to act as barriers to the proliferation of phage
31. An antisense expression vector, pTRK593 (Fig.
2), was first constructed and contained
the strong, Lactobacillus P6 promoter (12)
followed by the T7 terminator (TT7) in the high-copy-number
vector pTRKH2 (38). Five putative ORFs and one gene (early-
or middle-expressed ORF 1 and tac31A, and late-expressed ORFs 3, 4, 5, and 6) were cloned in the antisense orientation between
the P6 promoter and the T7 terminator of pTRK593. The antisense
constructs were prepared with either the entire coding region (anti-ORF
1, anti-ORF 1/tac31A, anti-ORF 3, and anti-ORF 6) or just
part of the coding region (anti-ORF 4H, 361-bp region; anti-ORF 5H,
493-bp region; and anti-ORF 6H, 467-bp region). In all cases, the 5'
portion of each coding region, including the Shine-Dalgarno sequence,
was used in an attempt to inhibit ribosome loading and negatively
impact translation. The function of only two of these ORFs is known.
Tac31A (formerly ORF 2 and Tac [52]) is the
transcriptional activator of the phage
31 late promoter (52). ORF 5 is highly homologous to ORF 27 of phage r1t, a
putative minor structural protein (50). EOP assays were
performed to measure the effectiveness of each construct in preventing
phage
31 proliferation (Table 3). The
results showed that none of the antisense cassettes cloned behind a
strong promoter on the high-copy-number pTRKH2-based replicon had an
effect on the ability of
31 to plaque on L. lactis subsp.
lactis NCK203.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 1.
Putative ORFs identified in a 3,584-bp region near the
right cohesive end of phage 31 (51). The overlapping
arrows of ORFs 4, 5, and 6 denote that the stop and start codons of
these ORFs overlap each other. The extent of homology to putative ORFs
of r1t (50) is shown in parentheses below each phage 31
ORF. The positions of cos and the phage-inducible promoter,
P15A10, are depicted by vertical arrows. The GenBank
accession no. for this sequence is AF022773.
|
|

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 2.
High-copy-number antisense expression vector pTRK593.
The P6 promoter fragment (BamHI/SalI) was cloned
from pLA6 (12). The T7 terminator was amplified as an
XhoI-SalI fragment (restriction sites underlined
in primers below) from the E. coli expression vector pET28a
(Novagen, Madison, Wis.) by using a 5' primer consisting of
5'-CTCGAGGAGAAGCCCGAAAGGAAGC-3' and a 3' primer
consisting of 5'-GTCGACTCCGGATATAGTTCCTC-3'. The
fragment was subsequently cloned into the XhoI site of the
base vector pTRKH2. *, unique restriction site.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Comparison of the effects of expression of the various
antisense cassettes from the high-copy-number vector with the effects
of those from the explosive replicon on the EOP of phage 31
|
|
One significant barrier to the successful use of an antisense strategy
may be that expression of sufficient levels of antisense
RNA is not
achieved at the appropriate point in the lytic cycle
to effectively
compete with expression of sense RNA from the phage
DNA. Attempts were
therefore made to increase the ratio of antisense
RNA to target mRNA by
utilizing a replicon which is explosively
amplified during the phage
infection cycle. To accomplish this,
the ORF 3, ORF 4H, ORF 5H, and ORF
6 antisense cassettes (P6::anti-ORF)
were removed from the
pTRK593-based vector by using
AviII-
XhoI
or
SmaI-
XhoI and subcloned into the
NruI-
SalI site of pTRK360
containing a
SalI-
XhoI T
T7 fragment (Fig.
2) in
the
SalI site
(pTRK601). pTRK601 is a low-copy-number vector
which contains
the putative phage

31 origin of replication,
ori31 (
37). These
ORFs were chosen because they
are expressed late in the phage
infection cycle, when the highest level
of antisense RNA expression
would be expected due to explosive
amplification of the vector
copy number by phage

31 infection.
ori31 alone on the low-copy-number
vector decreased the EOP
of

31 to about 0.36 and caused a marked
reduction in plaque size
(
37). Interestingly, a combination
of
ori31
and P6::anti-ORF 4H::T
T7 on the
low-copy-number vector
caused a further reduction in EOP to 0.11. Plaques were even more
erratic in size and somewhat turbid. The
ori31 plus P6::anti-ORF
3::T
T7 and
ori31 plus
P6::anti-ORF 5H::T
T7 constructs were
not
as effective, decreasing the EOP to 0.21 and 0.25, respectively,
with little effect on plaque size and appearance. The
ori31
plus
P6::anti-ORF 6::T
T7 construct had
no effect beyond that observed
with
ori31 alone.
To confirm that expression of antisense ORF 4H RNA was responsible for
the observed EOP reduction of phage

31 when combined
with
ori31, ORF 4H was cloned into pTRK601 in the same
orientation,
but without the P6 promoter. Results of EOP assays (Table
3)
showed that the presence of ORF 4H DNA alone had little to no
effect, other than that observed with
ori31, on the
proliferation
of phage

31, demonstrating that the anti-ORF 4H RNA
caused the
observed reduction in
EOP.
Effect of antisense constructs on phage
31 proliferation.
One-step growth curves were then performed to investigate the effects
of the ori31 plus P6::anti-ORF
4H::TT7 construct on
31 proliferation (Fig.
3). The presence of ori31
alone reduced the efficiency of center-of-infection formation (ECOI) by
phage
31 to 0.75 to 0.80, meaning that only 75 to 80% of the
initially infected cells were able to release phages capable of plaque
formation. ori31 alone also reduced the burst size fourfold,
from an average of 160 phages/cell with the control to 40 phages/cell
with ori31. With the ori31 plus
P6::anti-ORF 4H::TT7 construct, the
ECOI was further reduced to 0.35 to 0.45; only 35 to 45% of the
infected cells released viable phages. There was no further reduction
in burst size. ECOI assays were also performed with the
ori31 plus P6::anti-ORF
5H::TT7 and ori31 plus
P6::anti-ORF 3::TT7 constructs. In both
cases, the ECOI of
31 was reduced to approximately 0.65, a slight
reduction compared to that achieved with ori31 alone.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
One-step growth curves for 31 on NCK203 (the control)
(diamonds), NCK203 (pTRK360) (ori31 alone) (squares), and
NCK203 (pTRK603) (ori31 plus P6::anti-ORF
4H::TT7) (circles).
|
|
Levels of antisense RNA.
To evaluate the levels of antisense
RNA generated from these constructs, Northern slot blot hybridizations
were performed on RNA isolated from NCK203, NCK203
(P6::anti-ORF 4H::TT7) (high copy
number), NCK203 (ori31), and NCK203 (ori31 plus
P6::anti-ORF 4H::TT7) just before
and 40 min after infection with phage
31 (multiplicity of infection
[MOI] = 1 to 2). The RNA was probed with a
32P-labeled 72-bp oligonucleotide
(5'-TCTTGAGCGAGAAAAAGGAGATAATAATGAAAAGAATTTG TAGCATCTGTAAGCAAGAAAAAGAGCTAGATG-3') consisting
of sequences from the ORF 4H sense strand (complementary to the
antisense strand). Results are shown in Fig.
4A. As expected, high levels of anti-ORF 4H RNA were generated with the high-copy-number version of
P6::anti-ORF 4H::TT7 before phage
infection. After phage infection, however, the levels of anti-ORF 4H
RNA were reduced almost to background, indicating that the amount of
antisense RNA available was insufficient to interfere with sense ORF 4 mRNA. In contrast, significantly greater levels of anti-ORF 4H RNA were
detected with the combination of P6::anti-ORF
4H::TT7 and ori31 after phage
infection.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 4.
RNA slot blot hybridizations. (A) Levels of anti-ORF 4H
RNA produced before (time, 0 min) and after (time, 40 min) phage 31
infection of L. lactis subsp. lactis NCK203
carrying the various anti-ORF 4H constructs on the high-copy-number
vector or the explosive vector. The rows for NCK203 and NCK203
(ori31) show the low levels of nonspecific binding of the
72-bp anti-ORF 4H probe at 55°C. (B) Northern slot blot
hybridizations to measure the levels of ORF 4 and ORF 5 mRNA obtained
40 min after phage 31 infection of L. lactis subsp.
lactis NCK203 carrying the various anti-ORF 4H constructs on
the high-copy-number vector versus those of that carrying the explosive
vector. In all cases, no ORF 4 or ORF 5 mRNA was detected before phage
infection (data not shown).
|
|
To determine the effect of anti-ORF 4H RNA on expression of ORF 4 target mRNA from the

31 genome, the RNA was also probed
with a
32P-labeled ORF 4 PCR fragment. This fragment was amplified
from
the 3' end of the gene (primers
5'-CATATTCTTATGGAAATGTAGTTC-3'
and
5'-TCAGTCAATTTTTTGCTCCT-3') so that only sense ORF 4 mRNA,
and not the anti-ORF 4H RNA generated from the plasmid, would
be
detected. Figure
4B shows that, while
ori31 alone reduced
the
level of ORF 4 target mRNA somewhat, a combination of
ori31 with
P6::anti-ORF
4H::T
T7 significantly reduced the level of target
ORF 4 mRNA expressed by the phage. In comparison, the high-copy-number
version of anti-ORF 4H did not significantly impact the levels
of ORF 4 mRNA produced after phage infection. The same results
were obtained
when the RNA was probed with a
32P-labeled ORF 5 PCR
fragment. It was not possible to determine
whether or not this
reduction in sense mRNA was due to an antisense
effect, or to a
decrease in the number of available phages in
the
population.
New high-copy-number constructs utilizing the phage
31 late
promoter, P15A10.
The RNA slot blot data indicated
that antisense RNA levels with the P6::anti-ORF
4H::TT7 high-copy-number construct were reduced at the end of the phage
31 lytic cycle. Two new constructs were made
in an attempt to increase antisense RNA levels throughout the lytic
cycle without using ori31. In the first construct, the P6
promoter was replaced with an 888-bp mutated version of the phage
31
late promoter P15A10, which contains tac31A and
the promoter features (41, 52). In the mutated version,
designated P15A102x, a small inverted repeat downstream of
the transcription start sites was eliminated by site-directed
mutagenesis, resulting in a twofold increase in promoter activity. This
promoter is constitutive due to the presence of tac31A, but
is further induced upon phage infection (41, 52). The second
construct combined both promoters (P15A102x::P6::anti-ORF
4H::TT7) in an attempt to maintain high levels of
antisense RNA before phage infection and throughout the lytic cycle.
RNA slot blots (Fig. 4A) confirmed that higher anti-ORF 4H RNA levels
were present at the end of the lytic cycle, but neither construct was
able to inhibit phage proliferation (Table 3). Therefore, the
combination of ori31 and anti-ORF 4H RNA expression is
essential to the observed reduction in EOP.
Efficiency of the ori31 plus P6::anti-ORF
4H::TT7 phage defense system.
To determine
the efficiency of this antisense mechanism, growth curves for NCK203,
NCK203 (ori31), and NCK203 (ori31 plus P6::anti-ORF 4H::TT7) were measured in
the presence of varying levels of phage
31 (MOIs of 0.0001, 0.001, 0.01, and 0.1). Phage
31 lysed the NCK203 culture at each MOI within
5 h or less (Fig. 5, top). Both
ori31 and ori31 plus P6::anti-ORF
4H::TT7 provided NCK203 with significant
protection against
31, especially at the lower MOIs of 0.0001 and
0.001, where no lysis was observed after 5 to 6 h of growth.
Substantially more protection against
31 proliferation was achieved
with ori31 plus P6::anti-ORF
4H::TT7 at the higher MOI levels of 0.01 and 0.1 (Fig. 5, middle and bottom). Little to no lysis occurred at an MOI of
0.01, while lysis was significantly delayed at an MOI of 0.1 compared
to that observed with NCK203 with ori31 alone. Levels of
phage (PFU per milliliter) in the culture supernatants were also
monitored every hour from each sample (MOI, 0.01). Phage levels with
ori31 plus P6::anti-ORF 4H::TT7 were reduced at least 10-fold compared to
those of NCK203 (ori31) cultures and 50- to 100-fold
compared to those of NCK203 cultures over the course of growth (data
not shown).

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 5.
Effect of varying levels of phage 31 on the growth of
NCK203 (top), NCK203 (ori31) (middle), and NCK203
(ori31 plus P6::anti-ORF
4H::TT7) (bottom). The strains were propagated in
GM17, with 10 mM CaCl2 and erythromycin (2.5 µg/ml) when
required, to an optical density at 600 nm (OD600nm) of 0.15 before
the addition of phage 31.
|
|
Isolation of ori31r recombinant
phages.
One problem encountered with the use of ori31,
especially when provided on a high-copy-number vector, has been the
emergence of ori31-resistant (ori31r)
recombinant phages (14, 37). We investigated how readily ori31r phages emerged against the
low-copy-number ori31 plus P6::anti-ORF 4H::TT7 construct. In one experiment, four small
plaques of
31 formed on NCK203 (ori31 plus
P6::anti-ORF 4H::TT7) and two small plaques formed on NCK203 (low-copy-number ori31) were picked
and analyzed. EOP assays showed that the phages from each of the
plaques remained sensitive to both ori31 and
ori31 plus P6::anti-ORF
4H::TT7 (data not shown). This result was not
unexpected in that low-copy-number presentations of ori31
fail to select for resistant recombinant phages (37). In a
second experiment, phage
31 broth lysates were prepared with high
MOIs (MOI, >2) on both NCK203 (ori31) and NCK203
(ori31 plus P6::anti-ORF
4H::TT7). These lysates were then used to prepare
a second set of lysates in the same manner. Interestingly, a
significant number of ori31r phages [large
plaques on NCK203 (ori31)] had emerged by the second pass
through both NCK203 (ori31) and NCK203
(ori31 plus P6::anti-ORF 4H::TT7) when high MOIs were used.
Characterization of genomic DNA from four of these phages isolated on
NCK203 (ori31 plus P6::anti-ORF 4H::TT7) by restriction analysis (Fig.
6) showed that all four had different
restriction patterns from the parent phage,
31. Interestingly, the
31 restriction fragment encoding ori31 (E. Durmaz and
T. R. Klaenhammer, Abstr. 6th Symp. Lactic Acid Bacteria, abstr.
F28, 1999) was no longer present. This is likely due to a
recombinational exchange of phage
31 with host DNA (14,
37; Durmaz and Klaenhammer, Abstr. 6th Symp. Lactic Acid
Bacteria) that replaces ori31 with a new origin of
replication. Details of the exchange process and composition of the
sequences recovered by the recombinant phages are forthcoming in
another study (Durmaz and Klaenhammer, Abstr. 6th Symp. Lactic Acid
Bacteria). To date, however, no anti-ORF 4Hr phages have
been recovered.

View larger version (57K):
[in this window]
[in a new window]
|
FIG. 6.
HindIII restriction analysis of genomic
DNA from four ori31r recombinant or mutant
phages (labeled 31a to 31d) isolated on NCK203 (ori31
plus P6::anti-ORF 4H::TT7). The arrow
marks the band in phage 31 containing ori31.
|
|
 |
DISCUSSION |
In this study, sequence information from a region near the late
promoter and the right cohesive end of phage
31 (51) was used to develop antisense constructs in both a high-copy-number vector
and a low-copy-number explosive vector containing ori31, the
putative phage
31 origin of replication. When expressed from a
strong promoter on a high-copy-number vector, none of the putative coding regions used in the antisense constructs was able to inhibit the
proliferation of phage
31. One significant barrier to the successful
use of the high-copy-number strategy appeared to be that the levels of
antisense RNA product expressed by the cell were not high enough to
effectively compete with expression of sense mRNA generated during
phage infection. Indeed, when anti-ORF 4H RNA levels were measured 40 min after phage infection, few transcripts were detected for the
high-copy-number constructs (Fig. 4A). Increasing levels of anti-ORF 4H
RNA later in the lytic cycle by using the phage-inducible
31 late
promoter to drive antisense expression on the high-copy-number vector
also had no effect on EOP or plaque size (Table 3). These results are
similar to those obtained by Chen et al. (4), who found that
use of the powerful T7 promoter to drive expression of ribozyme RNA
targeted to a chloramphenicol acetyltransferase gene did not improve
the efficiency of the ribozyme in inhibiting chloramphenicol
acetyltransferase activity.
To increase the ratio of antisense RNA to sense mRNA generated in the
course of the phage infection, the
P6::anti-ORF::TT7 cassettes were
combined with ori31 on a low-copy-number vector. Upon phage
infection, ori31 acts as an alternative phage origin and
allows for explosive amplification of the vector, thereby increasing
the dose of antisense RNA remarkably. ORFs from the late region were
therefore considered the best targets since explosive expression of
antisense RNA would occur in the middle and later parts of the lytic
cycle. The higher level of expression which can be achieved using the
explosive amplicon was clearly illustrated in previous work with a gene
for
-galactosidase (lacZ.st) as a reporter
(41). Significantly greater levels of
-galactosidase activity were obtained during phage
31 infection when the
P15A10 promoter::lacZ.st cassette was
present on the low-copy-number vector containing ori31
rather than on a high-copy-number vector alone (2,100 Miller units
versus 700 Miller units, respectively [41]). In
addition to the increased dose of antisense RNA (Fig. 4A),
ori31 also results in a fourfold decrease in the burst size of phage
31, effectively lowering the levels of target sense mRNA
expressed by the phage (Fig. 4B). This combination of effects (increased antisense RNA and decreased target phage RNA) retarded phage
development and proved more effective than antisense constructs on the
high-copy-number vector.
Successful phage inhibition with the ori31 plus
P6::anti-ORF 4H::TT7 construct prompted
studies into its mechanism of action. One-step growth curves showed
that ori31 itself reduced the burst size fourfold, while
slightly reducing the ECOI to 0.75 to 0.80. When combined with
P6::anti-ORF 4H::TT7, no further
reduction in burst size was observed. However, the ECOI was reduced to
0.35 to 0.45, meaning only 35 to 45% of the phages could form
infective centers. Therefore, while ori31 effectively
decreased the number of phages released per infected cell, the
antisense RNA decreased the efficiency at which phage
31 could form
infective centers in the first place. The combination of the two
mechanisms was more effective than either of them alone.
While anti-ORF 4H RNA was clearly the most effective at inhibiting the
proliferation of phage
31 when combined with ori31, the
mechanism behind its ability to reduce the ECOI of phage
31 is
unknown. In addition to the translation initiation region
(Shine-Dalgarno and start codon), the 5' end of the ORF 4H fragment
used in the antisense construct contained the phage
31 right
cohesive end (cos). However, ORF 4H DNA alone, without the
P6 promoter, had little effect on the EOP of phage
31, confirming
that the expression of anti-ORF 4H RNA was responsible for the observed
phenotype, and not the presence of the cos site. ORF 4, whose function has not been determined, may encode a protein which is
more critical to the development of phage
31 than the other targets
tried (ORF 3, ORF 5H, and ORF 6), or a protein which is produced in
lower amounts. Therefore, decreasing its expression level below a
certain threshold in a percentage of cells may have resulted in fewer centers of infection. Alternatively, since anti-ORF 4H is targeted to a
polycistronic mRNA, the expression of one or more critical ORFs
downstream of ORF 4 may have been affected, thereby inhibiting phage
development. This explanation at first seems unlikely, since ori31 plus P6::anti-ORF
3::TT7, ori31 plus
P6::anti-ORF 5H::TT7, and
ori31 plus P6::anti-ORF
6::TT7, all of which are targeted to the same
polycistronic mRNA, had only a small effect, if any, on the EOP of
phage
31. However, the possibility exists that anti-ORF 4H RNA may
have been better able to interact with the target mRNA, either because
it was more stable or because its target was more accessible. Whichever
the case, the results presented here illustrate the importance of
targeting several different ORFs to determine which will be most
effective at inhibiting phage proliferation. This is especially true
when the function of many of the putative ORFs identified during
sequencing remains unknown.
Antisense RNA may act at two different levels to negatively impact
translation of the gene of interest (27). First, binding of
antisense RNA to the translation initiation region may inhibit ribosome
binding and subsequent translation of the message. This inhibition may
also affect downstream coding regions if they are translationally
coupled to the gene of interest. Second, binding of the antisense RNA
may destabilize the mRNA, making it more susceptible to degradation by
double-stranded RNases. Due to lack of antibodies to ORF 4 and ORF 5 gene products, the first scenario was not studied. However, some
evidence does exist that anti-ORF 4H RNA may negatively impact the
stability of the late mRNA containing ORF 4. As shown in Fig. 4B, the
levels of both ORF 4 and ORF 5 mRNA expressed from the phage genome
during infection were decreased when ori31 plus
P6::anti-ORF 4H::TT7 was present. At
this point, however, it is difficult to determine whether or not this
decrease in mRNA is due to the antisense mechanism or to a general
decrease in the number of phages present. When early- or
middle-expressed ORF 1 mRNA levels were measured in a similar manner to
that described for Fig. 4B, no decrease in ORF 1 mRNA levels during
phage infection was observed (data not shown), even in the presence of
ori31 plus P6::anti-ORF
4H::TT7. This result suggests that reduction in
ORF 4 and ORF 5 mRNA may be due at least in part to the destabilization of the late RNA transcript containing these overlapping ORFs. Further
work is needed to elucidate this mechanism.
While the success of the ori31 plus P6::anti-ORF
4H::TT7 is an exciting step forward, there remain
several serious challenges to overcome in the use of antisense
strategies. First, as is the case for a number of the novel phage
defense mechanisms in the literature, this strategy is specific for a
particular phage. Since it requires both a phage
31 origin and
coding region, it would not be effective against the heterogenous
population of phages which attack L. lactis. Second, few of
the lactococcal phage origins, which have been identified by genome
sequencing, have been shown to be as effective as ori31 or
ori50 in providing phage defense or in allowing explosive
replication when present on a vector (3, 53). Lastly, the
appearance and subsequent proliferation of recombinant or mutant phages
no longer sensitive to ori31 would limit the longevity of
this phage defense system in practice, since ori31 phages
were no longer inhibited by anti-ORF 4H RNA presented as the sole
defense mechanism.
Despite these drawbacks, this antisense strategy has the potential to
play a significant role in the arsenal of phage defense mechanisms
available for L. lactis. In addition to phage origins, antisense constructs could possibly be combined with any other phage
defenses that affect phage replication and/or burst size to increase
the ratio of antisense RNA to target phage mRNA. The availability of a
number of abortive systems which affect phage replication and/or burst
size may therefore extend the utility of this strategy or other
RNA-targeted strategies, such as ribozyme technology. Also, the
combination of antisense constructs which target ORFs from different
phases in the phage lytic cycle may prove more productive than a single
antisense construct. Availability of sequencing data and the recent
intense research into the molecular biology of the lactococcal
bacteriophages will surely identify targets that are fairly conserved
within a phage species, thereby making antisense strategies more
broadly applicable.
In conclusion, we have developed an effective phage defense strategy
which combines antisense technology with an explosive replicon to
deliver an enhanced ratio of antisense RNA to sense mRNA at the
appropriate time in the phage lytic cycle. These findings are
significant, not only because they represent another hurdle to phage
proliferation, but also because they offer clues in the design of more
potent antisense strategies or other strategies that target RNA.
 |
ACKNOWLEDGMENTS |
This research was supported by the Southeast Dairy Foods Research
Center (project no. 5-54201 and 5-45835-06369); Rhodia, Inc.; and the
USDA
NRICGP under project number 97-35503-4368.
We thank Martin Kullen, Evelyn Durmaz, and Soren Madsen for helpful
discussions and for critical reading of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Food Science, North Carolina State University, Campus Box 7624, Raleigh, NC 27695-7624. Phone: (919) 515-2971. Fax: (919) 515-7124. E-mail: Klaenhammer{at}ncsu.edu.
Paper no. FSR99-19 of the Department of Food Science, Southeast
Dairy Foods Research Center, North Carolina State University, Raleigh.
 |
REFERENCES |
| 1.
|
Alatossava, T., and T. R. Klaenhammer.
1991.
Molecular characterization of three small isometric-headed bacteriophages which vary in their sensitivity to the lactococcal phage resistance plasmid pTR2030.
Appl. Environ. Microbiol.
57:1346-1353[Abstract/Free Full Text].
|
| 2.
|
Allison, G. E., and T. R. Klaenhammer.
1998.
Phage resistance mechanisms in lactic acid bacteria.
Int. Dairy J.
8:207-226.
|
| 3.
|
Chandry, P. S.,
S. C. Moore,
J. D. Boyce,
B. E. Davidson, and A. J. Hillier.
1997.
Analysis of the DNA sequence, gene expression, origin of replication and modular structure of the Lactococcus lactis lytic bacteriophage sk1.
Mol. Microbiol.
26:49-64[CrossRef][Medline].
|
| 4.
|
Chen, H.,
G. Ferbeyre, and R. Cedergren.
1997.
Efficient hammerhead ribozyme and antisense RNA targeting in slow ribosome Escherichia coli mutant.
Nat. Biotechnol.
15:432-435[CrossRef][Medline].
|
| 5.
|
Chung, D. K.,
S. K. Chung, and C. A. Batt.
1992.
Antisense RNA directed against the major capsid protein of Lactococcus lactis subsp. cremoris bacteriophage F4-1 confers partial resistance to the host.
Appl. Microbiol. Biotechnol.
37:79-83[Medline].
|
| 6.
|
Coakley, M.,
G. F. Fitzgerald, and R. P. Ross.
1997.
Application and evaluation of the phage resistance- and bacteriocin-encoding plasmid pMRC01 for the improvement of dairy starter cultures.
Appl. Environ. Microbiol.
63:1434-1440[Abstract].
|
| 7.
|
Coffey, A.,
G. F. Fitzgerald, and C. Daly.
1989.
Identification and characterization of a plasmid encoding abortive infection from Lactococcus lactis ssp. lactis UC811.
Neth. Milk Dairy J.
43:229-244.
|
| 8.
|
Coleman, J.,
P. J. Green, and M. Inouye.
1984.
The use of RNAs complementary to specific mRNAs to regulate the expression of individual bacterial genes.
Cell
37:429-436[CrossRef][Medline].
|
| 9.
|
Daly, C.,
G. F. Fitzgerald, and R. Davis.
1996.
Biotechnology of lactic acid bacteria with special reference to bacteriophage resistance.
Antonie Leeuwenhoek
70:99-110.
|
| 10.
|
Dinsmore, P. K., and T. R. Klaenhammer.
1995.
Bacteriophage resistance in Lactococcus.
Mol. Biotechnol.
4:297-313[Medline].
|
| 11.
|
Dinsmore, P. K., and T. R. Klaenhammer.
1997.
Molecular characterization of a genomic region in a Lactococcus bacteriophage that is involved in its sensitivity to the phage defense mechanism AbiA.
J. Bacteriol.
179:2949-2957[Abstract/Free Full Text].
|
| 12.
|
Djordjevic, G. M.,
B. Bojovic,
N. Miladinov, and L. Topisorovic.
1997.
Cloning and molecular analysis of promoter sequences isolated from the chromosomal DNA of Lactobacillus acidophilus ATCC 4356.
Can. J. Microbiol.
43:61-69[Medline].
|
| 13.
|
Djordjevic, G. M.,
D. J. O'Sullivan,
S. A. Walker,
M. A. Conkling, and T. R. Klaenhammer.
1997.
Triggered-suicide system designed for bacteriophage defense of Lactococcus lactis.
J. Bacteriol.
179:6741-6748[Abstract/Free Full Text].
|
| 14.
|
Durmaz, E.,
D. J. O'Sullivan, and T. R. Klaenhammer.
1995.
Site-specific chromosomal disruptions of Lactococcus lactis NCK203 prevent the appearance of new recombinant lytic phage 31.1.
J. Dairy Sci.
78(Suppl.):109. (Abstract D42.)
|
| 15.
|
Ecker, J., and R. Davis.
1986.
Inhibition of gene expression in plant cells by expression of antisense RNA.
Proc. Natl. Acad. Sci. USA
83:5372-5376[Abstract/Free Full Text].
|
| 16.
|
Forde, A.,
C. Daly, and G. F. Fitzgerald.
1999.
Identification of four phage resistance plasmids from Lactococcus lactis subsp. cremoris HO2.
Appl. Environ. Microbiol.
65:1540-1547[Abstract/Free Full Text].
|
| 17.
|
Garbutt, K. C.,
J. Kraus, and B. L. Geller.
1997.
Bacteriophage resistance in Lactococcus lactis engineered by replacement of a gene for a bacteriophage receptor.
J. Dairy Sci.
80:1512-1519[Abstract].
|
| 18.
|
Garvey, P.,
D. van Sinderen,
D. P. Twomey,
C. Hill, and G. Fitzgerald.
1995.
Molecular genetics of bacteriophage and natural defense systems in the genus Lactococcus.
Int. Dairy J.
5:905-949[CrossRef].
|
| 19.
|
Hanahan, D.
1983.
Studies on transformation of Escherichia coli with plasmids.
J. Mol. Biol.
166:557-580[Medline].
|
| 20.
|
Harrington, A., and C. Hill.
1991.
Construction of a bacteriophage-resistant derivative of Lactococcus lactis subsp. lactis 425A by using the conjugal plasmid pNP40.
Appl. Environ. Microbiol.
57:3405-3409[Abstract/Free Full Text].
|
| 21.
|
Hill, C.,
K. Pierce, and T. R. Klaenhammer.
1989.
The conjugative plasmid pTR2030 encodes two bacteriophage defense mechanisms in lactococci, restriction/modification (R/M) and abortive infection (HSP+).
Appl. Environ. Microbiol.
55:2416-2419[Abstract/Free Full Text].
|
| 22.
|
Hill, C.,
L. A. Miller, and T. R. Klaenhammer.
1990.
Cloning, expression, and sequence determination of a bacteriophage fragment encoding bacteriophage resistance in Lactococcus lactis.
J. Bacteriol.
172:6419-6426[Abstract/Free Full Text].
|
| 23.
|
Hill, C.
1993.
Bacteriophage and bacteriophage resistance in lactic acid bacteria.
FEMS Microbiol. Rev.
12:87-108[CrossRef].
|
| 24.
|
Hirashima, A.,
S. Sawake,
Y. Inokuchi, and M. Inouye.
1986.
Engineering of the mRNA-interfering complementary RNA immune system against viral infection.
Proc. Natl. Acad. Sci. USA
83:7726-7730[Abstract/Free Full Text].
|
| 25.
|
Hirashima, A.,
S. Sawaki,
T. Mizuno,
N. Houba-Herin, and M. Inouye.
1989.
Artificial immune system against viral infection involving antisense RNA targeted to the 5'-terminal noncoding region of coliphage SP RNA.
J. Biochem.
106:163-166[Abstract/Free Full Text].
|
| 26.
|
Holo, H., and I. F. Nes.
1989.
High-frequency transformation, by electroporation, of Lactococcus lactis subsp. cremoris grown with glycine in osmotically stabilized media.
Appl. Environ. Microbiol.
55:3119-3123[Abstract/Free Full Text].
|
| 27.
|
Inouye, M.
1988.
Antisense RNA: its functions and applications in gene regulation a review.
Gene
72:25-34[CrossRef][Medline].
|
| 28.
|
Izant, J., and H. Weintraub.
1984.
Inhibition of thymidine kinase gene expression by anti-sense RNA: a molecular approach to genetic analysis.
Cell
36:1007-1115[CrossRef][Medline].
|
| 29.
|
Kelly, W.,
J. Dobson,
D. Jorck-Ramberg,
G. Fitzgerald, and C. Daly.
1990.
Introduction of bacteriophage resistance plasmids into commercial Lactococcus starter strains.
FEMS Microbiol. Rev.
87:P63. (Abstract.)
|
| 30.
|
Kim, J. H., and C. A. Batt.
1991.
Identification of a nucleotide sequence conserved in Lactococcus lactis bacteriophages.
Gene
98:95-100[CrossRef][Medline].
|
| 31.
|
Kim, J. H., and C. A. Batt.
1991.
Antisense RNA mediated bacteriophage resistance in Lactococcus lactis.
Appl. Environ. Microbiol.
57:1039-1045.
|
| 32.
|
Kim, S. G.,
Y.-C. Bor, and C. A. Batt.
1992.
Bacteriophage resistance in Lactococcus lactis ssp. lactis using antisense ribonucleic acid.
J. Dairy Sci.
75:1761-1767[Abstract].
|
| 33.
|
Klaenhammer, T. R., and G. F. Fitzgerald.
1994.
Bacteriophage and bacteriophage resistance, p. 106-168.
In
M. J. Gasson, and W. M. de Vos (ed.), Genetics and biotechnology of lactic acid bacteria. Blackie Academic and Professional, Glasgow, United Kingdom.
|
| 34.
|
Lubbers, M. W.,
N. R. Waterfield,
T. P. J. Beresford,
R. W. F. LePage, and A. W. Jarvis.
1995.
Sequencing and analysis of the prolate-headed lactococcal bacteriophage c2 and identification of the structural genes.
Appl. Environ. Microbiol.
61:4348-4356[Abstract].
|
| 35.
|
Moineau, S.,
E. Durmaz,
S. Pandian, and T. R. Klaenhammer.
1993.
Differentiation of two abortive mechanisms by using monoclonal antibodies directed toward lactococcal bacteriophage capsid proteins.
Appl. Environ. Microbiol.
59:208-212[Abstract/Free Full Text].
|
| 36.
|
Moineau, S.,
S. Pandian, and T. R. Klaenhammer.
1994.
Evolution of a lytic bacteriophage via DNA acquisition from the Lactococcus lactis chromosome.
Appl. Environ. Microbiol.
60:1832-1841[Abstract/Free Full Text].
|
| 37.
|
O'Sullivan, D. J.,
C. Hill, and T. R. Klaenhammer.
1993.
Effect of increasing the copy number of bacteriophage origins of replication, in trans, on incoming-phage proliferation.
Appl. Environ. Microbiol.
59:2449-2456[Abstract/Free Full Text].
|
| 38.
|
O'Sullivan, D. J., and T. R. Klaenhammer.
1993.
High and low copy number Lactococcus shuttle cloning vectors with features for clone screening.
Gene
137:227-231[CrossRef][Medline].
|
| 39.
|
O'Sullivan, D. J., and T. R. Klaenhammer.
1993.
Rapid mini-prep isolation of high-quality plasmid DNA from Lactococcus and Lactobacillus spp.
Appl. Environ. Microbiol.
59:2730-2733[Abstract/Free Full Text].
|
| 40.
|
O'Sullivan, D. J.,
K. Zagula, and T. R. Klaenhammer.
1995.
In vivo restriction by LlaI is encoded by three genes, arranged in an operon with llaIM, on the conjugative Lactococcus plasmid pTR2030.
J. Bacteriol.
177:134-143[Abstract/Free Full Text].
|
| 41.
|
O'Sullivan, D. J.,
S. A. Walker,
S. G. West, and T. R. Klaenhammer.
1996.
Development of an expression strategy using a lytic phage to trigger explosive plasmid amplification and gene expression.
Bio/Technology
14:82-87[CrossRef][Medline].
|
| 42.
|
O'Sullivan, D.,
A. Coffey,
G. F. Fitzgerald,
C. Hill, and R. P. Ross.
1998.
Design of a phage-insensitive lactococcal dairy starter via sequential transfer of naturally occurring conjugative plasmids.
Appl. Environ. Microbiol.
64:4618-4622[Abstract/Free Full Text].
|
| 43.
|
Raya, R. R.,
E. G. Kleeman,
J. B. Luchansky, and T. R. Klaenhammer.
1989.
Characterization of the temperate bacteriophage adh and plasmid transduction in Lactobacillus acidophilus ADH.
Appl. Environ. Microbiol.
55:2206-2213[Abstract/Free Full Text].
|
| 44.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 45.
|
Schouler, C.,
S. D. Ehrlich, and M.-C. Chopin.
1994.
Sequence and organization of the lactococcal prolate-headed bIL67 phage genome.
Microbiology
140:3061-3069[Abstract/Free Full Text].
|
| 46.
|
Simons, R. W.
1988.
Naturally occurring antisense RNA control a brief review.
Gene
72:35-44[CrossRef][Medline].
|
| 47.
|
Sing, W. D., and T. R. Klaenhammer.
1986.
Conjugal transfer of bacteriophage resistance determinants on pTR2030 into Streptococcus cremoris strains.
Appl. Environ. Microbiol.
51:1264-1271[Abstract/Free Full Text].
|
| 48.
|
Sing, W. D., and T. R. Klaenhammer.
1990.
Characteristics of phage abortion conferred in lactococci by the conjugal plasmid pTR2030.
J. Gen. Microbiol.
136:1807-1815.
|
| 49.
|
Terzaghi, B., and W. E. Sandine.
1975.
Improved medium for lactic streptococci and their bacteriophages.
Appl. Microbiol.
29:807-813.
|
| 50.
|
van Sinderen, D.,
H. Karsens,
J. Kok,
P. Terpstra,
M. H. J. Ruiters,
G. Venema, and A. Nauta.
1996.
Sequence analysis and molecular characterization of the temperate lactococcal bacteriophage r1t.
Mol. Microbiol.
19:1343-1355[Medline].
|
| 51.
|
Walker, S. A.,
C. S. Dombroski, and T. R. Klaenhammer.
1998.
Common elements regulating gene expression in temperate and lytic bacteriophages of Lactococcus species.
Appl. Environ. Microbiol.
64:1147-1152[Abstract/Free Full Text].
|
| 52.
|
Walker, S. A., and T. R. Klaenhammer.
1998.
Molecular characterization of a phage-inducible middle promoter and its transcriptional activator from the lactococcal bacteriophage 31.
J. Bacteriol.
180:921-931[Abstract/Free Full Text].
|
| 53.
|
Waterfield, N. R.,
M. W. Lubbers,
K. M. Polzin,
R. W. F. Le Page, and A. W. Jarvis.
1996.
An origin of DNA replication from Lactococcus lactis bacteriophage c2.
Appl. Environ. Microbiol.
62:1452-1453[Abstract].
|
| 54.
|
Yanisch-Perron, C.,
J. Vieira, and J. Messing.
1985.
Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors.
Gene
33:103-119[CrossRef][Medline].
|
Applied and Environmental Microbiology, January 2000, p. 310-319, Vol. 66, No. 1
0099-2240/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Sturino, J. M., Klaenhammer, T. R.
(2004). Antisense RNA Targeting of Primase Interferes with Bacteriophage Replication in Streptococcus thermophilus. Appl. Environ. Microbiol.
70: 1735-1743
[Abstract]
[Full Text]
-
Chen, G., Patten, C. L., Schellhorn, H. E.
(2003). Controlled Expression of an rpoS Antisense RNA Can Inhibit RpoS Function in Escherichia coli. Antimicrob. Agents Chemother.
47: 3485-3493
[Abstract]
[Full Text]
-
Durmaz, E., Madsen, S. M., Israelsen, H., Klaenhammer, T. R.
(2002). Lactococcus lactis Lytic Bacteriophages of the P335 Group Are Inhibited by Overexpression of a Truncated CI Repressor. J. Bacteriol.
184: 6532-6544
[Abstract]
[Full Text]
-
Pedersen, M. B., Jensen, P. R., Janzen, T., Nilsson, D.
(2002). Bacteriophage Resistance of a {Delta}thyA Mutant of Lactococcus lactis Blocked in DNA Replication. Appl. Environ. Microbiol.
68: 3010-3023
[Abstract]
[Full Text]
-
Sturino, J. M., Klaenhammer, T. R.
(2002). Expression of Antisense RNA Targeted against Streptococcus thermophilus Bacteriophages. Appl. Environ. Microbiol.
68: 588-596
[Abstract]
[Full Text]
-
Russell, W. M., Klaenhammer, T. R.
(2001). Identification and Cloning of gusA, Encoding a New {beta}-Glucuronidase from Lactobacillus gasseri ADH. Appl. Environ. Microbiol.
67: 1253-1261
[Abstract]
[Full Text]
-
McGrath, S., Fitzgerald, G. F., van Sinderen, D.
(2001). Improvement and Optimization of Two Engineered Phage Resistance Mechanisms in Lactococcus lactis. Appl. Environ. Microbiol.
67: 608-616
[Abstract]
[Full Text]